First choice	In patients with AF and TTR >70% on warfarin, it is reasonable to continue with VKA treatment, with careful monitoring to ensure that TTR remains >70%
Second choice	Substitution of VKA therapy with an NOAC may be considered in relation to the following: previous complications (major bleeding event, ischaemic stroke) on VKA therapy the SAMe-TT2R2 score (those with a score >2 are less likely to fare well on VKA therapy over the long term, and may be considered for NOAC therapy) the patient's individual values and preferences
Comment	The selection of an NOAC agent and dose should be based on specific patient characteristics. There is no preference for one NOAC over another.